Krystal Biotech's Q2 revenue rises 37% to $96 mln

Krystal Biotech

04/08/2025 12:08

Overview

Krystal Biotech Q2 product revenue rises to $96 mln, driven by VYJUVEK sales

Net income for Q2 increases to $38.3 mln, reflecting strong operational performance

VYJUVEK approved in Japan, enhancing global expansion efforts

Outlook

Krystal Biotech expects VYJUVEK Japan launch by end of 2025

Company plans VYJUVEK Germany launch in 3Q 2025

Krystal Biotech sees FY 2025 non-GAAP R&D and SG&A expenses $150-$175 mln

Company aims to report KB407 interim data by year-end

Result Drivers

VYJUVEK SALES - $96 mln in Q2 revenue attributed to strong VYJUVEK sales

JAPAN APPROVAL - VYJUVEK approved in Japan for DEB treatment, facilitating global expansion

HIGH COMPLIANCE - 82% patient compliance with weekly VYJUVEK treatment reported

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$96.04 mln
Q2 Net Income
$38.33 mln
Q2 Operating Expenses
$56.74 mln
Q2 Operating Income
$39.31 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Krystal Biotech Inc is $202.00, about 22.3% above its August 1 closing price of $156.98

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nGNXcMHWM

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)